Impact of Antihypertensive Therapy on Recurrence Risk of Ovarian Cancer for Bevacizumab-associated Hypertension

Active, not recruitingOBSERVATIONAL
Enrollment

9,464

Participants

Timeline

Start Date

May 20, 2024

Primary Completion Date

August 1, 2024

Study Completion Date

August 31, 2024

Conditions
Ovarian CancerAntiangiogenic-Associated HypertensionAdjuvant BevacizumabHypertension
Interventions
DRUG

arm A - angiotensin converting enzyme inhibitors (ACEi)

"Patients with ACEi monotherapy before or within 6 months following debulking surgery.~ACEi will be defined as any drugs from the Anatomical Therapeutic Classification C09AA with an indication for hypertension, including but not limited to: captopril, enalapril, lisinopril, perindopril, ramipril, quinapril"

DRUG

arm B - calcium channel blockers (CCBs)

"Patients with CCB monotherapy before or within 6 months following debulking surgery.~CCBs will be defined as any drugs from the Anatomical Therapeutic Classification C08CA with an indication for hypertension, including but not limited to: amlodipine, felodipine, isradipine, nicardipine, nifedipine"

DRUG

arm R - angiotensin receptor blockers ARB

"Patients with angiotensin receptor blocker (ARB) before or within 6 months following debulking surgery.~ARBs will be defined as any drugs from the Anatomical Therapeutic Classification C09CA with an indication for hypertension, including but not limited to: losartan, valsartan, irbesartan, candesartan or olmesartan medoxomil."

Trial Locations (2)

75005

Institut Curie, Paris

75013

Pitié-Salpêtrière, Paris

All Listed Sponsors
collaborator

Dr Floriane Jochum, Principal Investigator

UNKNOWN

collaborator

Institut Curie

OTHER

lead

Groupe Hospitalier Pitie-Salpetriere

OTHER

NCT06515678 - Impact of Antihypertensive Therapy on Recurrence Risk of Ovarian Cancer for Bevacizumab-associated Hypertension | Biotech Hunter | Biotech Hunter